Evidence map›Paper›PMID 39144141›Full record

ReviewFrontiers in immunology2024

Research advances on signaling pathways regulating the polarization of tumor-associated macrophages in lung cancer microenvironment.

Wenqiang Li, Quan Yuan, Mei Li, Xiaoyu He, Chen Shen, Yurui Luo, Yunze Tai, Yi Li, Zhiping Deng, Yao Luo

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Orchestration of Tumor-Associated Macrophages in the Tumor Cell-Macrophage-CD8International journal of biological sciences · 2025
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wenqiang Li *Department of Respiratory and Critical Care Medicine, Zigong First People's Hospital, Zigong, Sichuan, China.
Quan Yuan *Department of Respiratory and Critical Care Medicine, Zigong First People's Hospital, Zigong, Sichuan, China.
Mei LiWest China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xiaoyu HeDepartment of Clinical Medicine, North Sichuan Medical College, Nanchong, Sichuan, China.
Chen ShenWest China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yurui LuoWest China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yunze TaiWest China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yi LiDepartment of Respiratory and Critical Care Medicine, Zigong First People's Hospital, Zigong, Sichuan, China.
Zhiping DengDepartment of Respiratory and Critical Care Medicine, Zigong First People's Hospital, Zigong, Sichuan, China.
Yao LuoDepartment of Respiratory and Critical Care Medicine, Zigong First People's Hospital, Zigong, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer (LC) is one of the most common cancer worldwide. Tumor-associated macrophages (TAMs) are important component of the tumor microenvironment (TME) and are closely related to the stages of tumor occurrence, development, and metastasis. Macrophages are plastic and can differentiate into different phenotypes and functions under the influence of different signaling pathways in TME. The classically activated (M1-like) and alternatively activated (M2-like) represent the two polarization states of macrophages. M1 macrophages exhibit anti-tumor functions, while M2 macrophages are considered to support tumor cell survival and metastasis. Macrophage polarization involves complex signaling pathways, and blocking or regulating these signaling pathways to enhance macrophages' anti-tumor effects has become a research hotspot in recent years. At the same time, there have been new discoveries regarding the modulation of TAMs towards an anti-tumor phenotype by synthetic and natural drug components. Nanotechnology can better achieve combination therapy and targeted delivery of drugs, maximizing the efficacy of the drugs while minimizing side effects. Up to now, nanomedicines targeting the delivery of various active substances for reprogramming TAMs have made significant progress. In this review, we primarily provided a comprehensive overview of the signaling crosstalk between TAMs and various cells in the LC microenvironment. Additionally, the latest advancements in novel drugs and nano-based drug delivery systems (NDDSs) that target macrophages were also reviewed. Finally, we discussed the prospects of macrophages as therapeutic targets and the barriers to clinical translation.

Indexed as

Lung NeoplasmsSignal TransductionTumor-Associated MacrophagesTumor MicroenvironmentAnimalsHumansMacrophage ActivationLCNDDSspolarizationTAMsTME

Identifiers

PMID39144141
PMCPMC11321980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.